Team:LMU-Munich/Team

From 2010.igem.org

(Difference between revisions)
(What we did)
(What we did)
Line 128: Line 128:
If the colony PCR showed bands of the right size, the plasmids were extracted from overnight cultures and sequenced with forward and reverse BioBrick primers.
If the colony PCR showed bands of the right size, the plasmids were extracted from overnight cultures and sequenced with forward and reverse BioBrick primers.
-
In the end we succeeded in obtaining four sequenced BioBricks, though some BioBrick sequences turned out wrong. so that we only got 4 BioBricks although every ligation leaded to colonies after the transfection. Neither of our constructs was completed, so that we weren´t able to test them in eukarytic cell lines.  
+
In the end we succeeded in obtaining four correctly sequenced BioBricks. But since other necessary BioBrick sequences turned out wrong, neither of our systems could be completed and we were not able to test them in eukarytic cell lines.  
-
In addition, we found out that a CMV-promoter we ordered from the registry was in fact a lacI gene and therefore some BioBricks just couldn´t be right.
+
In addition, we found out that the CMV-promoter we ordered from the BioBrick registry was in fact a lacI gene, which resulted in the procrastination of our plan. We have sent the correction to the registry to facilitate future teams.
Line 144: Line 144:
*BBa_K368019: TEV-Protease+p14*+TEVrecognition site
*BBa_K368019: TEV-Protease+p14*+TEVrecognition site
-
<b>Sources, helpers and supporters:</b>
+
<b>Supervisors</b>
* Prof. Dr. Angelika Böttger :  
* Prof. Dr. Angelika Böttger :  
Line 152: Line 152:
** Human Bak:  her assistant Erika Clement gave us appropriate cDNA
** Human Bak:  her assistant Erika Clement gave us appropriate cDNA
-
* Dr. Arnim Weber: submitted us a vector with human Bak
+
<b> Plasmid and sequence sources <b>
 +
 
 +
* Dr. Arnim Weber: provided us with human Bak plasmid
* Dr. Philipe Soriano: <html>
* Dr. Philipe Soriano: <html>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17225864?dopt=Abstract"> (Raymond CS et al: High-Efficiency FLP and PhiC31 Site-Specific Recombination in Mammalian Cells (2007))</a>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17225864?dopt=Abstract"> (Raymond CS et al: High-Efficiency FLP and PhiC31 Site-Specific Recombination in Mammalian Cells (2007))</a>
</html>
</html>
** Sequences of attB and attP site
** Sequences of attB and attP site
-
** PhiC31o was bought via addgene
+
** PhiC31o was bought via Addgene
-
* Knop, M (Heidelberg): <html>
+
* Dr. Michael Knop:(Heidelberg): <html>
<a href ="http://www.ncbi.nlm.nih.gov/pubmed?term=Efficient%20protein%20depletion%20by%20genetically%20controlled%20deprotection%20of%20a%20dormant%20N-degron">(Knop et al.: Efficient protein depletion by genetically controlled deprotection of a dormant N-degron (2009))</a>
<a href ="http://www.ncbi.nlm.nih.gov/pubmed?term=Efficient%20protein%20depletion%20by%20genetically%20controlled%20deprotection%20of%20a%20dormant%20N-degron">(Knop et al.: Efficient protein depletion by genetically controlled deprotection of a dormant N-degron (2009))</a>
</html>
</html>
 +
** provided us with:
** TEVrecognition site+N-degron+SF3b155
** TEVrecognition site+N-degron+SF3b155
** TEV-Protease+p14*+TEVrecognition site
** TEV-Protease+p14*+TEVrecognition site
Line 171: Line 174:
* Prof. Dr. Andreas Brachmann:  
* Prof. Dr. Andreas Brachmann:  
** Sequenced our samples
** Sequenced our samples
-
* Partsregistry:
+
* Partsregistry provided us with:
** eGFP (BBa_I714891)
** eGFP (BBa_I714891)
** CMV-Promoter (BBa_J52034: this part was wrong: its lacI !!!)
** CMV-Promoter (BBa_J52034: this part was wrong: its lacI !!!)
Line 177: Line 180:
-
We went to the Oktoberfest, LMU Munich and the municipal secretary and asked a few questions about synthetic biology: [[Team:LMU-Munich/Human practice|Human practice]]
+
As our project for human practice, we carried out a survey about synthetic biology on the general public at the Oktoberfest, LMU Munich and the Municipal Secretary: [[Team:LMU-Munich/Human practice|Human practice]]
== '''Where we are from''' ==
== '''Where we are from''' ==

Revision as of 17:04, 25 October 2010


Team LMU iGEM 2010

Our team picture
Also our team


Who we are

We are a team constisting of biologists, biochemists, chemists and bioinformatics and four faculty advisors... The LMU team is competing for the first time.

Advisors

Undergrads

Who is in charge of what?

Press Nicolas Keller, Marisa Kurz
Sponsoring Sabine Wagner, Franziska Haefele
Pathway Tobias Bauer, Emanuel Stiegeler, Benny Clanner
ApoControl Julia Bartels, Jara Radeck, Mengzhe Grace Wang
Homepage Tatyana Goldberg, Jens Popken
Coordination/Organisation Jara Radeck
Contact igemlmu@yahoo.de

What we did

Short description of our work, our results and our supporters


To establish our two systems “Cut’N’Survive” and “Jump-Or-Die” for selecting cells by apoptosis, we first built the necessary constructs. Therefore we searched for sources of the DNA parts involved and several labs kindly supported us by sending the plasmids and sequences we needed, which are listed below.

Most genes and promoters were amplificated per PCR with overhang-primers with the BioBrick prefix or suffix. If the sequence contained a EcoRI-, PstI-, XbaI-, SpeI- or NotI- restriction site, we used mutagenesis primers and fused both DNA parts by fusion PCR. Fortunately all PCRs worked in spite of several problems with the touch down PCR and the fusion PCR.The PCR products were then tested by agarose gel electrophoresis if they are of the right length. We sequenced the plasmids due to poor results from PCR products' sequencing.

In parallel, we made competent cells and multiplied the ccdB (death gene)-vectors with different antibiotic resistances.

All components were then digested with the appropriate restriction enzymes. The PCR products were cleaned with a PCR purification kit and the ccdB-vectors were dephosphorylated to reduce false ligations.

We ligated our constructs and several intermediates with the 3A-assembly according to the schedule. The ligations were transformed to E.coli DH5α strains and selected by antibiotics. The colonies were later picked and the insertion of the construct was confirmed by colony PCR.

If the colony PCR showed bands of the right size, the plasmids were extracted from overnight cultures and sequenced with forward and reverse BioBrick primers.

In the end we succeeded in obtaining four correctly sequenced BioBricks. But since other necessary BioBrick sequences turned out wrong, neither of our systems could be completed and we were not able to test them in eukarytic cell lines.

In addition, we found out that the CMV-promoter we ordered from the BioBrick registry was in fact a lacI gene, which resulted in the procrastination of our plan. We have sent the correction to the registry to facilitate future teams.


Our notebook with detailed descriptions can be found here: ApoControl notebook

The protocols we used are listed here: Protocols

The Biobricks we could submit:

  • BBa_K368004: attP+eGFP+SV40PA
  • BBa_K368011: eGFP+SV40PA
  • BBa_K368016: TEVrecognition site+N-degron+SF3b155
  • BBa_K368019: TEV-Protease+p14*+TEVrecognition site

Supervisors

  • Prof. Dr. Angelika Böttger :
    • prevTRE (tet-on CMV promoter; inducible by doxycycline in special cell lines)
    • supported the construction ideas and would have given us the cells and mediums we would have needed
    • SV40PA (Polyadenylation site): gave us a vector containing it
    • Human Bak: her assistant Erika Clement gave us appropriate cDNA

Plasmid and sequence sources <b>


As our project for human practice, we carried out a survey about synthetic biology on the general public at the Oktoberfest, LMU Munich and the Municipal Secretary: Human practice

Where we are from

We are students at Ludwigs-Maximilians-University in Munich, Germany.


Biozentrum
our bio-center (photos courtesy of www.stbam2.bayern.de)